Celcuity Adds Oncology Commercialization Veteran to Board Ahead of Key Drug Launch
Event summary
- Celcuity appoints Charles (Chip) R. Romp to its Board of Directors on February 12, 2026.
- Romp brings 25 years of oncology commercialization experience, including leadership roles at Seagen and Genentech.
- Gedatolisib, Celcuity's lead drug candidate, is in Phase 3 trials for advanced breast cancer with potential approval later in 2026.
- Romp is currently CEO of Secura Bio and previously oversaw commercialization of multiple oncology drugs at Seagen.
The big picture
Celcuity's appointment of Romp underscores its focus on commercializing gedatolisib, a potential blockbuster therapy for advanced breast cancer. The move comes as the company prepares for a critical regulatory decision later this year, highlighting the strategic importance of oncology commercialization expertise at the board level. Romp's background in launching multiple successful oncology drugs positions Celcuity to navigate the complex market dynamics of targeted cancer therapies.
What we're watching
- Commercialization Strategy
- How Romp's experience will shape Celcuity's approach to launching gedatolisib in a competitive oncology market.
- Regulatory Timeline
- Whether Celcuity can secure FDA approval for gedatolisib under the Real-Time Oncology Review program as anticipated.
- Pipeline Expansion
- The pace at which Celcuity advances its other clinical programs beyond gedatolisib.
Related topics